YOLFTbeta
Tibet Weixinkang Medicine Co Ltd

Tibet Weixinkang Medicine Co Ltd

603676 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

8.10CNY-0.14 (-1.70%)

Price History

Full chart

Market Stats

Previous Close8.24
Open8.22
Day Range8.06 – 8.27
52-Week Range7.82 – 12.08
Volume1.42M
Market Cap3.96B
P/E (TTM)20.20
Forward P/E0.00
EPS0.45
Dividend Yield3.60%
Beta-0.08
50-Day Avg9.02
200-Day Avg9.95

About

Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. It offers APIs; multivitamins and pediatric multivitamins for injections; concentrate of trace elements solution for infusion; compound and pediatric compound amino acid injections; iron sucrose, multiple electrolytes, potassium aspartate and magnesium aspartate, carbohydrate and electrolyte, pentoxifylline, piracetam, and dopamine hydrochloride injections; and acetylcysteine solution for inhalation. The company was formerly known as Weixinkang Medicine Youxian Gongsi and changed its name to Tibet Weixinkang Medicine Co., Ltd. in 2015. Tibet Weixinkang Medicine Co., Ltd. was founded in 2002 and is based in Lhasa, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Feng Liu
  • Employees763
  • HeadquartersBuilding 4, Lhasa, China, 850000, China
  • Websitehttps://www.wxkpharma.com

Leadership

  • Mr. Feng LiuVice Chairman & Deputy GM · b. 1973
  • Ms. Yanxia ZhengFinancial Director · b. 1979
  • Mr. Shigong ChenDeputy GM & Director · b. 1973
  • Mr. Haibo YuBoard Secretary · b. 1979
  • Mr. Xiaobing ZhouDeputy General Manager · b. 1976

Financials

Income Statement

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue342.30M390.79M440.23M426.36M420.38M746.32M740.96M715.67M1.03B1.40B1.32B1.30B1.14B
Growth (%)-+14.17%+12.65%-3.15%-1.40%+77.54%-0.72%-3.41%+44.43%+35.31%-5.43%-1.69%-12.65%
Cost of Revenue115.63M125.17M161.21M161.65M178.01M404.84M393.92M385.12M502.71M672.06M651.24M604.25M437.81M
Gross Profit226.67M265.62M279.02M264.71M242.37M341.48M347.04M330.55M530.92M726.48M671.41M695.98M697.94M
Gross Margin66.22%67.97%63.38%62.09%57.66%45.76%46.84%46.19%51.36%51.95%50.76%53.53%61.45%
Operating Expense125.84M138.39M158.25M151.39M153.70M264.84M291.82M271.27M428.63M563.88M496.44M415.13M438.59M
Operating Income100.83M127.23M120.77M113.32M88.67M76.64M55.22M59.28M102.28M162.60M174.96M280.86M259.34M
Operating Margin29.46%32.56%27.43%26.58%21.09%10.27%7.45%8.28%9.90%11.63%13.23%21.60%22.83%
EBITDA107.31M146.34M138.36M145.64M137.03M100.90M92.76M102.00M145.95M218.81M258.96M323.26M334.69M
EBITDA Margin31.35%37.45%31.43%34.16%32.60%13.52%12.52%14.25%14.12%15.65%19.58%24.86%29.47%
Net Income82.95M106.74M112.93M114.92M101.59M73.44M55.68M58.42M95.91M176.96M214.02M246.17M232.85M
Net Income Margin24.23%27.31%25.65%26.95%24.17%9.84%7.51%8.16%9.28%12.65%16.18%18.93%20.50%
R&D-23.24M30.92M33.82M25.01M24.44M29.14M23.20M38.02M72.45M112.82M116.01M110.62M
R&D as % of Total Revenue-5.95%7.02%7.93%5.95%3.28%3.93%3.24%3.68%5.18%8.53%8.92%9.74%
Interest Expense-60.55K77.79K72.00K3.11M617.12K01.29M2.07M275.52K430.45K224.70K224.60K
Interest Expense % of Total Revenue-0.02%0.02%0.02%0.74%0.08%0.00%0.18%0.20%0.02%0.03%0.02%0.02%

Balance Sheet

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets309.30M363.37M508.75M552.36M1.02B1.23B1.30B1.36B1.50B1.66B1.78B1.85B1.87B
Total Liabilities61.52M77.09M105.82M92.94M158.58M337.33M374.56M376.85M428.31M444.13M436.55M468.24M390.49M
Total Equity235.76M286.19M402.90M459.42M858.04M897.64M930.05M983.21M1.07B1.22B1.34B1.39B1.48B
Cash99.79M77.56M136.31M89.27M75.37M154.28M159.68M219.52M243.77M519.32M269.43M216.44M212.22M
Total Debt-----26.60M-6.35M4.81M5.79M3.82M5.27M-
Net Debt-99.79M-77.56M-136.31M-89.27M-75.37M-127.67M-159.68M-213.17M-238.96M-513.53M-261.74M-211.17M-

Cash Flow

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow88.59M118.47M114.47M103.79M63.30M83.17M106.34M133.70M170.69M246.15M256.67M372.78M185.53M
Investing Cash Flow-94.63M-68.48M-55.43M-94.27M-377.74M3.50M-77.67M-54.82M-152.71M105.21M-389.21M-209.96M-
Financing Cash Flow-1.10M-72.23M-282.00K-56.55M290.55M-7.76M-13.28M-19.04M6.27M-75.82M-102.44M-217.40M-
Capital Expenditure97.29M70.97M43.29M26.40M77.76M94.50M43.65M54.35M55.60M77.69M70.81M58.18M83.92M
Free Cash Flow-8.70M47.50M71.18M77.39M-14.46M-11.33M62.69M79.35M115.09M168.46M170.30M314.61M101.62M
Dividends Paid-62.82M-56.55M3.45M34.36M23.27M19.04M40.19M69.63M97.84M177.85M163.44M
FCF to OCF-9.82%40.09%62.18%74.56%-22.85%-13.62%58.95%59.35%67.43%68.44%66.35%84.39%54.77%
Dividend Paid to FCF-132.26%-73.08%-23.87%-303.34%37.11%23.99%34.92%41.33%57.45%56.53%160.84%

Earnings

Report DateSep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Aug 27, 2020Oct 29, 2020Dec 31, 2020Apr 28, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021May 10, 2022Aug 24, 2022Oct 27, 2022Dec 31, 2022Apr 25, 2023
EPS Estimate-----------------------
EPS Actual0.030.060.080.050.020.020.050.040.020.030.030.040.040.030.040.080.070.030.090.150.110.060.14
Surprise-----------------------
Timing------------------After-hoursPre-marketAfter-hours-Pre-market

Key Statistics & Ratios

Market Cap3.96B
Enterprise Value2.84B
Trailing P/E20.20
Forward P/E0.00
Price / Sales3.49
Price / Book2.52
EPS0.45
Book Value3.56
Revenue (TTM)1.13B
Gross Profit (TTM)679.36M
EBITDA198.50M
Profit Margin17.02%
Operating Margin16.17%
Return on Equity12.74%
Return on Assets5.04%
Shares Outstanding435.16M
Shares Float93.88M
Beta-0.08
Dividend Yield3.60%
Dividend Rate0.33
Payout Ratio72.67%

Dividends

20231×
0.23Jun 2, 2023
20221×
0.16Jun 6, 2022
20211×
0.10Jun 2, 2021
20201×
0.04Jun 2, 2020
20191×
0.06May 30, 2019
20181×
0.08May 30, 2018